News

Both the parties will conduct a two-year research program for the development of small molecules targeting the cell surface protein ADAM8, which has been linked to tumor survival,

PAH is a life-threatening disease involving endothelial dysfunction, pulmonary vasoconstriction, vascular remodeling, pulmonary fibrosis, and right ventricular hypertrophy. In addition, PAH involves skeletal muscle dysfunction that contributes to

The company said that IND remains on partial clinical hold with regard to doses above 0.24 mg/kg/day in healthy volunteers. The randomized, single-blind, placebo-controlled TKM-Ebola Phase I clinical

In February 2015, the company submitted the investigational new drug (IND) application for Actimmune in the treatment of FA. The company has also announced plans to initiate a

Further to this deal, Celgene will purchase Mesoblast stock and hold a six-month right of first refusal to certain disease fields. As part of the agreement, Celgene will

Under the deal, the data will also be used to inform target selection, target validation, indication selection and repositioning. The deal will see Genomics partner with Eisai’s new

Currently, the company has multiple Phase III trials underway evaluating ADS-5102 for this indication, which currently has no FDA-approved treatment options. ADS-5102 (amantadine HCl) is a high dose,

At the new facility, the company will produce both Penfill cartridges and FlexPen prefilled insulin injection pens for the Russian market. Located in Technopark Grabtsevo in the Kaluga

The company’s US unit Eisai employs about 1,800 people and its operations include research and development, manufacturing, sales and marketing and administrative functions. Eisai chairman and CEO Yuji